<DOC>
	<DOCNO>NCT01135368</DOCNO>
	<brief_summary>The purpose study measure safety , efficacy quality life lansoprazole patient reflux disease five year period .</brief_summary>
	<brief_title>Safety Efficacy Lansoprazole Patients With Reflux Disease</brief_title>
	<detailed_description>Lansoprazole currently approve Germany treatment erosive reflux esophagitis active duodenal gastric ulcer disease , long-term treatment include maintenance heal reflux esophagitis duodenal ulcer disease treatment pathological hypersecretory condition Zollinger-Ellison syndrome . This study conduct evaluate safety , efficacy quality life patient receive five year treatment lansoprazole .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<criteria>Had Gastro Esophageal Reflux disease without oesophagitis . Had history heartburn least 5 day per week past 6 month receive longterm treatment proton pump inhibitor two week ( without proton pump inhibitor treatment ) prior enrolment . History surgery stomach oesophagus . Gastric ulcer ( included healing gastric ulcer ) . Duodenal ulcer ( included heal duodenal ulcer ) . Bleeding ( melena , hematemesis ) . Severe concomitant disease ( cancer , cardiovascular , renal , hepatic disease ) . Barrett oesophagus dysplasia . Complicated esophagitis ( oesophageal strictures ulcer ) . Treatment proton pump inhibitor Histamine receptor 2 ( H2 ) antagonists within previous two week . Pregnancy , wish become pregnant , breast feeding . Treatment non steroidal antiinflammatory drug , treatment acetylsalicylic acid ( aspirin ) &gt; 100 mg/day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>GERD</keyword>
	<keyword>Gastroesophageal Reflux Disease</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>